Fosmidomycin for malaria
暂无分享,去创建一个
Jochen Wiesner | J. Wiesner | H. Jomaa | B. Lell | A. Adegnika | S. Issifou | P. Kremsner | S. Borrmann | T. Baranek | Hassan Jomaa | M. Missinou | P. Matsiegui | Steffen Borrmann | Michel A Missinou | Saadou Issifou | Pierre-Blaise Matsiegui | Ayola A Adegnika | Peter G Kremsner | Bertrand Lell | Andreas Schindler | Ronald Binder | Thomas Baranek | A. Schindler | R. Binder
[1] W. Wernsdorfer,et al. Drug sensitivity of Plasmodium falciparum in Gabon. Activity correlations between various antimalarials. , 1994, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.
[2] H. Lichtenthaler,et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.
[3] B. Mordmüller,et al. [Malaria therapy in the era of chloroquine resistance]. , 1998, Wiener klinische Wochenschrift.
[4] M. Nishida,et al. Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic , 1982, Antimicrobial Agents and Chemotherapy.
[5] T. Konishi,et al. Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies. , 1985, International journal of clinical pharmacology, therapy, and toxicology.